NASDAQ:SYBX Synlogic (SYBX) News Today $0.56 +0.02 (+3.70%) (As of 05/26/2023 ET) Add Compare Share Share Today's Range$0.54▼$0.5750-Day Range$0.49▼$0.6852-Week Range$0.45▼$1.35Volume67,261 shsAverage Volume723,192 shsMarket Capitalization$38.20 millionP/E RatioN/ADividend YieldN/APrice Target$6.75 HeadlinesProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Get Synlogic News Delivered to You Automatically Sign up to receive the latest news and ratings for SYBX and its competitors with MarketBeat's FREE daily newsletter. Email Address SYBX Media Mentions By Week SYBX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SYBX News Sentiment▼0.400.72▲Average Medical News Sentiment SYBX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SYBX Articles This Week▼42▲SYBX Articles Average Week All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineSynlogic Announces Data Presentations at the 2023 Synthetic Biology: Engineering, Evolution & Design (SEED) Conferencefinance.yahoo.com - May 24 at 7:03 AMSynlogic to Present at the Jefferies Global Healthcare Conferencefinance.yahoo.com - May 23 at 10:56 AMQ3 2023 Earnings Estimate for Synlogic, Inc. (NASDAQ:SYBX) Issued By HC Wainwrightamericanbankingnews.com - May 19 at 2:36 AMHC Wainwright & Co. Reiterates Synlogic (SYBX) Buy Recommendationmsn.com - May 16 at 3:52 AMH.C. Wainwright Sticks to Its Buy Rating for Synlogic (SYBX)markets.businessinsider.com - May 15 at 7:51 AMSynlogic First Quarter 2023 Earnings: Beats Expectationsfinance.yahoo.com - May 13 at 9:20 AMChardan Capital Sticks to Its Buy Rating for Synlogic (SYBX)markets.businessinsider.com - May 12 at 12:45 AMSynlogic: Q1 Earnings Insightsmsn.com - May 11 at 7:45 PMSynlogic, Inc.: Synlogic Reports First Quarter 2023 Financial Results and Provides Business Updatefinanznachrichten.de - May 11 at 9:42 AMSynlogic Reports First Quarter 2023 Financial Results and Provides Business Updatefinance.yahoo.com - May 11 at 9:42 AMSynlogic, Inc. (SYBX) Reports Q1 Loss, Lags Revenue Estimatesfinance.yahoo.com - May 11 at 9:42 AMSynlogic Soars on Orphan Drug Status Win for SYNB1934msn.com - May 10 at 6:41 PMAnalysts Estimate Synlogic, Inc. (SYBX) to Report a Decline in Earnings: What to Look Out forfinance.yahoo.com - May 4 at 12:19 PMSynlogic, Inc. (NASDAQ:SYBX) Forecasted to Post Q1 2023 Earnings of ($0.27) Per Shareamericanbankingnews.com - May 2 at 1:28 AMShort Interest in Synlogic, Inc. (NASDAQ:SYBX) Increases By 19.0%americanbankingnews.com - April 30 at 7:28 AMSynlogic, Inc. (NASDAQ:SYBX) to Post FY2024 Earnings of ($1.09) Per Share, HC Wainwright Forecastsamericanbankingnews.com - April 29 at 5:10 AMSynlogic (NASDAQ:SYBX) Earns Buy Rating from HC Wainwrightamericanbankingnews.com - April 28 at 7:38 AMSynlogic's (SYBX) Buy Rating Reaffirmed at HC Wainwrightamericanbankingnews.com - April 28 at 7:04 AMSynlogic, Inc. (NASDAQ:SYBX) Insider Aoife Brennan Sells 19,042 Sharesamericanbankingnews.com - April 7 at 6:54 AMSynlogic, Inc. to Post Q1 2023 Earnings of ($0.23) Per Share, Oppenheimer Forecasts (NASDAQ:SYBX)americanbankingnews.com - April 5 at 1:20 AMSynlogic, Inc. Expected to Post Q1 2023 Earnings of ($0.24) Per Share (NASDAQ:SYBX)americanbankingnews.com - April 4 at 1:18 AMChardan Capital Cuts Synlogic (NASDAQ:SYBX) Price Target to $5.50americanbankingnews.com - April 1 at 5:00 AMSynlogic, Inc. (NASDAQ:SYBX) Forecasted to Post Q1 2024 Earnings of ($0.16) Per Shareamericanbankingnews.com - March 31 at 7:58 AMSynlogic, Inc. (NASDAQ:SYBX) Sees Significant Drop in Short Interestamericanbankingnews.com - March 29 at 7:28 AMSynlogic Receives Positive Opinion on Orphan Designation from the European Medicines Agency for SYNB1934 for the Treatment of Phenylketonuriafinance.yahoo.com - March 28 at 8:14 AMSynlogic Announces Data Presentations at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meetingfinance.yahoo.com - March 20 at 8:25 AMSynlogic to Present at the Oppenheimer 33rd Annual Healthcare Conferencefinance.yahoo.com - March 8 at 9:07 AMSynlogic To Present Three Data Presentations at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meetingfinance.yahoo.com - March 7 at 9:30 AMSYBX.Oreuters.com - March 3 at 11:45 PMSynlogic Stock (NASDAQ:SYBX), Quotes and News Summarybenzinga.com - February 11 at 9:36 AMSynlogic Announces Participation in Upcoming Investor and Industry Conferencesfinance.yahoo.com - January 24 at 7:03 AMSynlogic Receives Rare Pediatric Disease Designation from FDA for SYNB1934 for Phenylketonuria (PKU)finance.yahoo.com - January 19 at 10:16 AMSynlogic, Inc. (SYBX) Upgraded to Buy: Here's Whyfinance.yahoo.com - January 16 at 2:12 PMEven after rising 15% this past week, Synlogic (NASDAQ:SYBX) shareholders are still down 90% over the past five yearsfinance.yahoo.com - January 14 at 12:00 PMSynlogic Provides Corporate Update and Outlook for 2023finance.yahoo.com - January 5 at 8:26 AMSYBX.A - Synlogic Inc | Stock Price & Latest News | Reutersreuters.com - December 31 at 6:26 PMSynlogic's Experimental Drug Lowers Urinary Oxalate In Gastric Bypass Patientsfinance.yahoo.com - December 23 at 9:58 AMSynlogic Announces Achievement of Proof of Concept for SYNB8802 in Enteric Hyperoxaluria Based on Urinary Oxalate Lowering in Phase 1b Studyfinance.yahoo.com - December 15 at 9:21 AMSVB Securities Reaffirms Their Buy Rating on Synlogic (SYBX)markets.businessinsider.com - November 14 at 5:25 AMSynlogic Touts Positive Data From Rare Inherited Disorder Trial, Pivotal Study To Start Next Yearfinance.yahoo.com - October 26 at 2:33 AMSynlogic Stock: SYNB1934 Advances To Phase 3 (NASDAQ:SYBX) - Seeking Alphaseekingalpha.com - October 20 at 8:38 AMSYBX stock gains after early Phase 2 data for phenylketonuria candidates (NASDAQ:SYBX) - Seeking Alphaseekingalpha.com - October 18 at 11:29 PMSynlogic shares are trading higher after the company announced top-line Phase 2 data for phenylketonuria, saying "both strains demonstrated clinically meaningful reductions in fasting plasma Phe." - Synlogic (NASDAQ:SYBX) - Benzingabenzinga.com - October 18 at 11:29 PMOppenheimer Raises Synlogic's Price Target to $8 From $6, Maintains Outperform Rating - Marketscreener.commarketscreener.com - October 18 at 6:29 PMSynlogic Announces Positive Top-Line Phase 2 Data for Phenylketonuria (PKU); SYNB1934 Advances to Phase 3 - GlobeNewswireglobenewswire.com - October 18 at 6:29 PMSynlogic Announces Top-Line Phase 2 Data For Phenylketonuria; Says 'Both strains demonstrated clinically meaningful reductions in fasting plasma Phe' - Synlogic (NASDAQ:SYBX) - Benzingabenzinga.com - October 18 at 8:12 AMSynlogic Announces Positive Top-Line Phase 2 Data for Phenylketonuria (PKU); SYNB1934 Advances to Phase 3 - Yahoo Financefinance.yahoo.com - October 18 at 8:12 AMSynlogic Announces Positive Top-Line Phase 2 Data for Phenylketonuria (PKU); SYNB1934 Advances to Phase 3finance.yahoo.com - October 18 at 8:12 AMSYBX.OQ - Synlogic Inc | Stock Price & Latest News | Reutersreuters.com - October 11 at 12:19 PMSoaring Eagle Acquisition : EXPLANATORY NOTE - Form 8-K - Marketscreener.commarketscreener.com - October 5 at 12:48 AM Get Synlogic News Delivered to You Automatically Sign up to receive the latest news and ratings for SYBX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Acurx Pharmaceuticals News Today Avalo Therapeutics News Today Checkpoint Therapeutics News Today Neoleukin Therapeutics News Today Satsuma Pharmaceuticals News Today Unity Biotechnology News Today Kala Pharmaceuticals News Today Coeptis Therapeutics News Today FSD Pharma News Today NuCana News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat Originals This page (NASDAQ:SYBX) was last updated on 5/27/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Synlogic, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.